MedTrace Logo

A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1

NCT06667453 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-04-28

No results posted yet for this study

Summary

The purpose of this study is to learn about the effects of an investigational medicine, PGN-EDODM1, to see how safe and tolerable multiple administrations of PGN-EDODM1 are for people with myotonic dystrophy type 1 (DM1) compared to placebo.

Conditions

  • Myotonic Dystrophy 1

Interventions

DRUG

PGN-EDODM1

Administered by intravenous (IV) infusion

OTHER

Placebo

Administered by intravenous (IV) infusion

Sponsors & Collaborators

  • PepGen Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-10
Primary Completion
2027-03-31
Completion
2027-03-31
FDA Drug
Yes

Countries

  • Canada
  • New Zealand
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06667453 on ClinicalTrials.gov